Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.32 |
| ▸ | HTR3B | O95264 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365524 | 0.80 | MEN1 (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL10238742 | 0.79 | CCR1 (0.32) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL19365669 | 0.74 | HTR3E (0.31) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL19365510 | 0.72 | CHRNA3 (0.34) | — | |
| SCHEMBL19365307 | 0.70 | ALOX5 (0.33) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL12396466 | 0.69 | HTR2A (0.38) | ALDH1A1 | |
| SCHEMBL19699030 | 0.67 | MEN1 (0.45) | ALDH1A1 | |
| SCHEMBL19670531 | 0.66 | AR (0.32) | — | |
| SCHEMBL19417814 | 0.66 | HRH4 (0.37) | ALDH1A1 | |
| SCHEMBL16237549 | 0.63 | HTR3E (0.37) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | HTR3E 2698/4885HTR3B 2869/4885HTR3A 3393/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | HTR3E 2698/4885HTR3B 2869/4885HTR3A 3393/4885 |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | HTR3E 2698/4885HTR3B 2869/4885HTR3A 3393/4885 |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | HTR3E 2698/4885HTR3B 2869/4885HTR3A 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.